Axsome Malta patents expiration

1. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(13 years from now)

US11648232 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(14 years from now)

US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness with a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime ...


How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic